KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing

Clinica Chimica Acta

Volumn 412, Issue 17-18, 2011, Pages 1578-1581

  French, Deborah ^a   Smith, Andrew ^a   Powers, Martin P ^a,b   Wu, Alan H B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colorectal cancer; Gene chip array; KRAS mutation detection

Indexed keywords

K RAS PROTEIN;

ARTICLE; CLINICAL LABORATORY; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE K RAS; PRIORITY JOURNAL; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM;

COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79959289732     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.05.001     Document Type: Article

References (21)

1. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
2. Cappuzzo F., Varella-Garcia M., Finocchiaro G., et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorrectal cancer patients. Br J Cancer 2008, 99:83-89.
3. Di Fore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated with Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
4. van der Weyden L., Adams D.J. The Ras-association domain family (RASSF) members and their role in human tumorigenesis. Biochim Biophys Acta 2007, 1776:58-85.
5. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998, 90:675-684.
6. Edkins S., O'Meara S., Parker A., et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006, 5(8):928-932.
7. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
8. European Medicines Agency Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Erbitux http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000558/WC500059829.pdf.
9. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096.
10. United Healthcare Insurance policy statement on KRAS testing. https://www.unitedhealthcareonline.com/b2c/CmaAction.do?channelId=40e71d1962210210VgnVCM2000003010b10a.
11. BlueCross BlueShield position statement on KRAS testing http://mcgs.bcbsfl.com/?doc=KRAS%20Mutation%20Analysis%20in%20Metastatic%20Colorectal%20Cancer.
12. Cigna Government Services Local Coverage Determination on KRAS testing http://www.cignagovernmentservices.com/partb/coverage/lcd/draft_lcds/nc/NC_DL30200.html.
13. WellMark Insurance policy statement on KRAS testing http://www.wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/policies/KRAS_Mutation.aspx.
14. Tol J., Dijkstra J.R., Vink-Borger M.E., et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010, 14(8):2122-2131.
15. Zuo Z., Chen S.S., Chandra P.K., et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009, 22:1023-1031.
16. Arcila M., Lau C., Nafa K., Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma: roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011, 13(1):64-73.
17. Lang A.H., Drexel H., Geller-Rhomberg S., et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 2011, 13(1):23-28.
18. Er T.K., Chang Y.S., Yeh K.T., Chang T.J., Chang J.G. Comparison of two different screening methods for the KRAS mutation in colorectal cancer. Clin Lab 2010, 56(5-6):175-186.
19. Weichert W., Schewe C., Lehmann A., et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnosis. Comparison of methods and impact of histology. J Mol Diagn 2010, 12(1):35-42.
20. Dufort S., Richard M.-J., de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009, 391:166-168.
21. Nikiforova M.N., Lynch R.A., Biddinger P.W., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88(5):2318-2326.